HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autoantibodies and the risk of cardiovascular events.

AbstractOBJECTIVE:
Inflammation and autoimmunity are associated with increased cardiovascular (CV) risk in patients with rheumatoid arthritis. This association may also be present in those without rheumatic diseases. Our purpose was to determine whether rheumatoid factor (RF), antinuclear antibody (ANA), and cyclic citrullinated peptide antibody (CCP) positivity are associated with increased risk of CV events and overall mortality in those with and without rheumatic diseases.
METHODS:
We performed a population-based cohort study of all subjects who had a RF and/or ANA test performed between January 1, 1990, and January 1, 2000, and/or CCP test performed between September 1, 2003, and January 1, 2005, with followup until April 1, 2007. Outcomes were ascertained using diagnostic indices from complete medical records, including CV events [myocardial infarction (MI), heart failure (HF), and peripheral vascular disease (PVD)] and mortality. Cox models were used to analyze the data.
RESULTS:
There were 6783 subjects with RF, 7852 with ANA, and 299 with CCP testing. Of these, 10.4%, 23.9%, and 14.7% were positive for RF, ANA, and CCP, respectively. Adjusting for age, sex, calendar year, comorbidity, and rheumatic disease, RF and ANA positivity were significant predictors of CV events [hazard ratio (HR) 1.24 and 1.26] and death (HR 1.43 and 1.18). Adjusting for age, CCP positivity was associated with CV events, but this association was not statistically significant (HR 3.1; 95% CI 0.8, 12.3).
CONCLUSION:
RF and ANA positivity are significant predictors of CV events and mortality in both those with and those without rheumatic diseases. These results support the role of immune dysregulation in the etiology of CV disease.
AuthorsKimberly P Liang, Hilal Maradit Kremers, Cynthia S Crowson, Melissa R Snyder, Terry M Therneau, Veronique L Roger, Sherine E Gabriel
JournalThe Journal of rheumatology (J Rheumatol) Vol. 36 Issue 11 Pg. 2462-9 (Nov 2009) ISSN: 0315-162X [Print] Canada
PMID19833748 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Antinuclear
  • Autoantibodies
  • Peptides, Cyclic
  • cyclic citrullinated peptide
  • Rheumatoid Factor
Topics
  • Adult
  • Antibodies, Antinuclear (adverse effects, blood, immunology)
  • Autoantibodies (adverse effects, blood, immunology)
  • Cardiovascular Diseases (blood, immunology, mortality)
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Peptides, Cyclic (adverse effects, blood, immunology)
  • Predictive Value of Tests
  • Rheumatoid Factor (adverse effects, blood, immunology)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: